Wall Street analysts expect Grifols SA to report Q2 2026 revenue of $2.23 billion and earnings of $0.27 per share, while the stock currently trades at $7.80 compared to an average price target of $10.87.
The primary focus for investors remains the company’s ability to generate positive free cash flow (FCF) and achieve its deleveraging targets following a period of intense balance sheet scrutiny.
Grifols is working to maintain the double-digit growth trajectory of its core immunoglobulin franchise, which surged 12.8% in the first half of the year. Investors will also look for updates on the integration of Biotest and the operational efficiency of new plasma centers in Egypt to support long-term margin expansion goals.